PIDOTIMOD IN PAUCISYMPTOMATIC SARS-CoV2 INFECTED PATIENTS
Background and purpose: Currently clinicians wide world are facing with SARS-CoV-2 pandemy, whose clinical features include fever, dry cough, fatigue and acute respiratory distress syndrome (ARDS) which can progress to life threatening sequelae. Aim of this study is to evaluate both efficacy and saf...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2020-06-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | http://mjhid.org/index.php/mjhid/article/view/4259 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846095547925004288 |
|---|---|
| author | Claudio Ucciferri Barone Mirko Jacopo Vecchiet Katia Falasca |
| author_facet | Claudio Ucciferri Barone Mirko Jacopo Vecchiet Katia Falasca |
| author_sort | Claudio Ucciferri |
| collection | DOAJ |
| description | Background and purpose: Currently clinicians wide world are facing with SARS-CoV-2 pandemy, whose clinical features include fever, dry cough, fatigue and acute respiratory distress syndrome (ARDS) which can progress to life threatening sequelae. Aim of this study is to evaluate both efficacy and safety of pidotimod in paucisymptomatic SARS-CoV-2 patients without any evidence of concurrent pneumonia.
Methods: Twenty SARS-CoV-2 1:1 allocated (pidotimod vs symptomatic therapy) Brescia-COVID Respiratory Severity Scale 0 patients were enrolled and complaining fever, cough without any sign of respiratory failure. None of them required standard regimens or hospitalization.
Results: At two-brace cohort analysis no significant selection bias between groups were reported. In the absence of relevant drug-induced side effects or disease progression during therapy, the experimental group presented an earlier clinical resolution than the control one (Group A vs Group B: 4.10±2.18 vs 7.50±2.63 days; 95%CI: 1.13 – 5.67, SE: 1.08; p=0.006), as confirmed from a linear regression analysis.
Conclusions: Pidotimod regimens in selected SARS-COV2 patients could be a viable option to induce symptoms regression, as an earlier defervescence protects from the indolent course of cytokine cascade activation. Rebalancing the immune status with pidotimod may also have prevented the evolution of the infection in patients. |
| format | Article |
| id | doaj-art-dfa3545999e9469588eb8dba9ca8ab55 |
| institution | Kabale University |
| issn | 2035-3006 |
| language | English |
| publishDate | 2020-06-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Mediterranean Journal of Hematology and Infectious Diseases |
| spelling | doaj-art-dfa3545999e9469588eb8dba9ca8ab552025-01-02T10:22:55ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062020-06-0112110.4084/mjhid.2020.048PIDOTIMOD IN PAUCISYMPTOMATIC SARS-CoV2 INFECTED PATIENTSClaudio Ucciferri0Barone Mirko1Jacopo Vecchiet2Katia Falasca3Clinic of Infectious Diseases – Department of Medicine and Science of Aging, University “G. d’Annunzio” Chieti-Pescara– Italy Department of Medicine and Health Sciences 'Vincenzo Tiberio', University of Molise, I-86100 Campobasso, Italy.Department of General and Thoracic Surgery, University Hospital of Chieti, Chieti, Italy.Clinic of Infectious Diseases – Department of Medicine and Science of Aging, University “G. d’Annunzio” Chieti-Pescara– ItalyClinic of Infectious Diseases – Department of Medicine and Science of Aging, University “G. d’Annunzio” Chieti-Pescara– ItalyBackground and purpose: Currently clinicians wide world are facing with SARS-CoV-2 pandemy, whose clinical features include fever, dry cough, fatigue and acute respiratory distress syndrome (ARDS) which can progress to life threatening sequelae. Aim of this study is to evaluate both efficacy and safety of pidotimod in paucisymptomatic SARS-CoV-2 patients without any evidence of concurrent pneumonia. Methods: Twenty SARS-CoV-2 1:1 allocated (pidotimod vs symptomatic therapy) Brescia-COVID Respiratory Severity Scale 0 patients were enrolled and complaining fever, cough without any sign of respiratory failure. None of them required standard regimens or hospitalization. Results: At two-brace cohort analysis no significant selection bias between groups were reported. In the absence of relevant drug-induced side effects or disease progression during therapy, the experimental group presented an earlier clinical resolution than the control one (Group A vs Group B: 4.10±2.18 vs 7.50±2.63 days; 95%CI: 1.13 – 5.67, SE: 1.08; p=0.006), as confirmed from a linear regression analysis. Conclusions: Pidotimod regimens in selected SARS-COV2 patients could be a viable option to induce symptoms regression, as an earlier defervescence protects from the indolent course of cytokine cascade activation. Rebalancing the immune status with pidotimod may also have prevented the evolution of the infection in patients.http://mjhid.org/index.php/mjhid/article/view/4259immunomodulatory, COVID-19, treatment, safety |
| spellingShingle | Claudio Ucciferri Barone Mirko Jacopo Vecchiet Katia Falasca PIDOTIMOD IN PAUCISYMPTOMATIC SARS-CoV2 INFECTED PATIENTS Mediterranean Journal of Hematology and Infectious Diseases immunomodulatory, COVID-19, treatment, safety |
| title | PIDOTIMOD IN PAUCISYMPTOMATIC SARS-CoV2 INFECTED PATIENTS |
| title_full | PIDOTIMOD IN PAUCISYMPTOMATIC SARS-CoV2 INFECTED PATIENTS |
| title_fullStr | PIDOTIMOD IN PAUCISYMPTOMATIC SARS-CoV2 INFECTED PATIENTS |
| title_full_unstemmed | PIDOTIMOD IN PAUCISYMPTOMATIC SARS-CoV2 INFECTED PATIENTS |
| title_short | PIDOTIMOD IN PAUCISYMPTOMATIC SARS-CoV2 INFECTED PATIENTS |
| title_sort | pidotimod in paucisymptomatic sars cov2 infected patients |
| topic | immunomodulatory, COVID-19, treatment, safety |
| url | http://mjhid.org/index.php/mjhid/article/view/4259 |
| work_keys_str_mv | AT claudioucciferri pidotimodinpaucisymptomaticsarscov2infectedpatients AT baronemirko pidotimodinpaucisymptomaticsarscov2infectedpatients AT jacopovecchiet pidotimodinpaucisymptomaticsarscov2infectedpatients AT katiafalasca pidotimodinpaucisymptomaticsarscov2infectedpatients |